Myocardial dysfunction in sepsis: Mechanisms and therapeutic implications

European Heart Journal

Volumn 20, Issue 10, 1999, Pages 715-724

  Price, S ^a   Anning, P B ^a   Mitchell, J A ^a   Evans, T W ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Myocardial dysfunction; Nitric oxide; Sepsis

Indexed keywords

CORTICOSTEROID; CYTOKINE; FREE RADICAL; HYPERTENSIVE AGENT; INOTROPIC AGENT; LIPOPOLYSACCHARIDE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTANOID;

CORONARY ARTERY BLOOD FLOW; HEART FUNCTION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; INFLAMMATION; MYOCARDIAL DISEASE; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK; VASCULAR ENDOTHELIUM; VASODILATATION;

CORONARY CIRCULATION; CYTOKINES; ENDOTHELIUM, VASCULAR; HEART; HUMANS; NITRIC OXIDE SYNTHASE; PROSTAGLANDINS; SHOCK, SEPTIC; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0033135184     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1998.1358     Document Type: Review

References (93)

1. Balk BA. The septic syndrome. Definition and clinical implications. Crit Care Clinics 1998; 5: 1-8.
2. Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parillo JE. Endotoxemia in human septic shock. Chest 1991; 99: 169-75.
3. Bone RC, Balk RA, Cerra FB et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine (see comments). Chest 1992; 101: 1644-55.
4. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-74.
5. Parrillo JE, Parker MM, Natanson C et al. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy (see comments). Ann Intern Med 1990; 113: 227-42.
6. Parker MM, Shelhamer JH, Bacharach SL et al. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 1984; 100: 483-90.
7. Parker MM, Shelhamer JH, Natanson C, Alling DW, Parrillo JE. Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: Heart rate as an early predictor of prognosis. Crit Care Med 1987; 15: 923-9.
8. Ognibene FP, Parker MM, Natanson C, Shelhamer JH, Parrillo JE. Depressed left ventricular performance. Response to volume infusion in patients with sepsis and septic shock. Chest 1988; 93: 903-10.
9. Walley KRW. Principles of Critical Care, Vol. 2. In: Hall JBS, Wood GA, eds. McGraw-Hill, Inc., 1992: 1393-1416.
10. Alella A. Interrelation between cardiac oxygen consumption and coronary blood flow. Am J Physiol 1955; 183: 5703.
11. Cunnion RE, Schaer GL, Parker MM, Natanson C, Parrillo JE. The coronary circulation in human septic shock. Circulation 1986; 73: 637-44.
12. Herbertson MJ, Werner HA, Russell JA, Iversen K, Walley KR. Myocardial oxygen extraction ratio is decreased during endotoxemia in pigs. J Appl Physiol 1995; 79: 479-86.
13. Powell RJ, Machiedo GW, Rush Jr BF, Dikdan G. Oxygen free radicals: Effect on red cell deformability in sepsis. Crit Care Med 1991; 19: 732-5.
14. Dhainaut MD. Coronary haemodynamics and myocardial metabolism of lactate, free fatty acids, glucose and ketones in patients with septic shock. Circulation 1987; 75: 533-41.
15. Solomon MA, Correa R, Alexander HR et al. Myocardial energy metabolism and morphology in a canine model of sepsis. Am J Physiol 1994; 266: H757-68.
16. Van Lambalgen AA, van Kraats AA, Mulder MF, Teerlink T, van den Bos GC. High-energy phosphates in heart, liver, kidney, and skeletal muscle of endotoxemic rats. Am J Physiol 1994; 266: H1581-7.
17. Goode HF, Webster NR. Free radicals and antioxidants in sepsis. Crit Care Med 1993; 21: 1770-6.
18. Goode HFC, Walker HC, Howdle BE, Webster PD. Decreased antioxidant status and increased lipid peroxidation in patients with septic shock and secondary organ dysfunction. Crit Care Med 1995; 23: 646-51.
19. Zingarelli B, Day BJ, Crapo JD, Salzman AL, Szabo C. The potential role of peroxynitrite in the vascular contractile and cellular energetic failure in endotoxic shock. Br J Pharmacol 1997; 120: 259-67.
20. Szabo C. The pathophysiological role of peroxynitrite in shock, inflammation, and ischemia-reperfusion injury. Shock 1996; 6: 79-88.
21. Wiggers CJ. Myocardial depression in shock. A survey of cardiodynamic studies. Am Heart J 1947; 33: 633-50.
22. Parrillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, Schuette W. A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest 1985; 76: 1539-53.
23. Reilly JM, Cunnion RE, Burch-Whitman C, Parker MM, Shelhamer JH, Parrillo JE. A circulating myocardial depressant substance is associated with cardiac dysfunction and peripheral hypoperfusion (lactic acidemia) in patients with septic shock (see comments). Chest 1989; 95: 1072-80.
24. Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 1996; 183: 949-58.
25. Suffredini AF, Fromm RE, Parker MM et al. The cardiovascular response of normal humans to the administration of endotoxin (see comments). N Engl J Med 1989; 321: 280-7.
26. Granton JTG, Allard CM, van Eden MF, Walley S. Leukocytes and decreased left-ventricular contractility during endotoxaemia in rabbits. Am J Crit Care Med 1997; 155: 1977-83.
27. Walley KRS, Poon BY. Activated neutrophils adhere to and decrease fractional shortening of activated rat cardiac myocytes (Abstr). Am J Resp Crit Care Med 1998; 157: A103.
28. Vincent J-LB, Marecaux J. Administration of anti-TNF antibody improves left ventricular function in septic shock patients. Chest 1992; 101: 810-15.
29. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992; 257: 387-9.
30. Liu SF, Newton R, Evans TW, Barnes PJ. Differential regulation of cyclo-oxygenase-1 and cyclo-oxygenase-2 gene expression by lipopolysaccharide treatment in vivo in the rat. Clin Sci Colch 1996; 90: 301-6.
31. Reines HDH, Cook PV, Wise JA, Rambo WC. Plasma thromboxane concentrations are raised in patients dying with septic shock. Lancet 1982; 8291: 174-5.
32. Bishop-Bailey DL, Warner SW, Chen TD, Mitchell G. Characterization of the induction of nitric oxide synthase and cyclo-oxygenase in rat sorta in organ culture. Bri J Pharmacol 1997; 121: 125-33.
33. Sessa WC. The nitric oxide synthase family of proteins. J Vasc Res 1994; 31: 131-43.
34. Calver AC, Vallance J. Nitric oxide and the control of human vascular tone in health and disease. Eur J Med 1993; 2: 48-53.
35. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 1992; 12: 3051-64.
36. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 1990; 101: 746-52.
37. Loscalzo JW. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 1995; 38: 87-104.
38. Balligand JLU, Kelly D, Kobzik RA et al. Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. J Clin Invest 1993; 91: 2314-19.
39. Brady AJ, Poole-Wilson PA, Harding SE, Warren JB. Nitric oxide production within cardiac myocytes reduces their contractility in endotoxemia. Am J Physiol 1992; 263: H1963-6.
40. Grocott-Mason R, Fort S, Lewis MJ, Shah AM. Myocardial relaxant effect of exogenous nitric oxide in isolated ejecting hearts. Am J Physiol 1994; 266: H1699-705.
41. Wahler GMD. Nitric oxide donor SIN-1 inhibits mammalian cardiac calcium current through cGMP-dependent protein kinase. Am J Physiol 1995; 261: C45-C54.
42. Shah AM, Spurgeon HA, Sollott SJ, Talo A, Lakatta EG. 8-bromo-cGMP reduces the myofilament response to Ca2+ in intact cardiac myocytes. Circ Res 1994; 74: 970-8.
43. Shah AM, Mebazaa A, Wetzel RC, Lakatta EG. Novel cardiac myofilament desensitizing factor released by endocardial and vascular endothelial cells. Circulation 1994; 89: 2492-7.
44. Fischmeister RH. Cyclic AMP phosphodiesterases and calcium current regulation in cardiac cells. Life Sci 1991; 48: 2365-76.
45. Morris SMB. New insights into the regulation of inducible nitric oxide synthesis. Am J Physiol 1994; 266: E829-39.
46. Schini VBB, Vanhoutte R. Inducible nitric oxide synthase in vascular smooth muscle. Arzneimittelforschung 1994; 44: 432-5.
47. Balligand JL, Ungureanu-Longrois D, Simmons WW et al. Cytokine-inducible nitric oxide synthase (iNOS) expression in cardiac myocytes. Characterization and regulation of iNOS expression and detection of iNOS activity in single cardiac myocytes in vitro. J Biol Chem 1994; 269: 27580-8.
48. Cook HTB, Jansen AJ, Taylor AS, Loi GM, Cattell RK. Cellular localization of inducible nitric oxide synthase in experimental endotoxic shock in the rat. Clini Sci 1994; 87: 179-86.
49. Zingarelli B, Wong Ocmh, Salzman AL, Szabo C. Peroxynitrite-mediated DNA strand breakage activates polyadenosine diphosphate ribosyl synthetase and causes cellular energy depletion in macrophages stimulated with bacterial lipopolysaccharide. J Immunol 1996; 156: 350-8.
50. Szabo C, Saunders C, Salzman Ocmal. Peroxynitrite causes energy depletion and increases permeability via activation of poly (ADP-ribose) synthetase in pulmonary epithelial cells. Am J Respir Cell Mol Biol 1997; 16: 105-9.
51. Laycock SK, McMurray J, Kane KA, Parratt JR. Effects of the xanthine oxidase system on cardiac function in anaesthetised rats. Free Radic Biol Med 1993; 15: 249-55.
52. Lopez BLL, Xhristopher GL, Ma TA. Peroxynitrite, the product of nitric oxide and superoxide, causes myocardial injury in the isolated perfused rat heart. Cor Art Dis 1997; 8: 149-53.
53. Brutsaert DLM, Sipido AL. Effects of damaging the endocardial surface on the mechanical performance of isolated cardiac muscle. Circ Res 1988; 62: 358-66.
54. Mohan PB. Positive inotropic effects of acetylcholine; Role of the endocardial endothelium. Circulation 1994; 90: 1649.
55. Schoemaker IEM, Andries AL, Brutsaert LJ. Role of endocardial endothelium in positive inotropic effect of vasopressin. Am J Physiol 1990; 259: H1148-H1151.
56. Meulemans ALA, Brutsaert LJ. Endocardial endothelium mediated positive inotropic response to alpha 1-adrenoceptor agonist in mammalian heart. Mol Cell Cardiol 1990; 22: 667-85.
57. Shah AM. Paracrine modulation of heart cell function by endothelial cells. Cardiovasc Res 1996; 31: 847-67.
58. Brutsaert DLA. The endocardial endothelium. Am J Physiol 1992; 263: H985-1002.
59. Hayes MA, Yau EH, Timmins AC, Hinds CJ, Watson D. Response of critically ill patients to treatment aimed at achieving supranormal oxygen delivery and consumption. Relationship to outcome (see comments). Chest 1993; 103: 886-95.
60. Martin CV, Potie X. Use and misuse of catecholamines: Combination in septic shock patients. In: Vincent J-L, ed. Yearbook Of Intensive Care and Emergency Medicine. Springer, 1997: 289-301.
61. Rackow EC, Astiz ME, Kim YB, Weil MH. Monophosphoryl lipid A blocks the hemodynamic effects of lethal endotoxemia. J Lab Clin Med 1989; 113: 112-17.
62. Astiz ME, Rackow EC, Kim YB, Weil MH. Monophosphoryl lipid A induces tolerance to the lethal hemodynamic effects of endotoxemia. Circ Shock 1991; 33: 92-7.
63. Bone RC, Balk RA, Fein AM et al. A Second Large Controlled Clinical Study of E5, a Monoclonal Antibody to Endotoxin: Results of a Prospective, Multicenter, Randomized, Controlled Trial. The E5 Sepsis Study Group [see comments] [published erratum appears in Crit Care Med 1995 23: 1616. Crit Care Med 1995; 23: 994-1006.
64. Ziegler EJC, Fisher J, Sprung CJ. Treatment of Gram-negative bacteraemia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomised, double-blind, placebo-controlled trial. N Engl J Med 1991; 324: 429-436.
65. Shumer W. Steroids in the treatment of septic shock. Ann Surg 1976; 184: 333-41.
66. Bollaert PEC, Levy C, Debouverie B, Audibert M, Larcan G. Reversal of late septic shock with supraphysiological doses of hydrocortisone. Crit Care Med 1998; 26: 645-51.
67. Soulsby ME, Jacobs ER, Perlmutter BH, Bone RC. Protection of myocardial function during endotoxin shock by ibuprofen. Prostaglandins Leukot Med 1984; 13: 295-305.
68. Bernard GRW, Russell AP, Schien JA et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The ibuprofen in sepsis study group. N Eng J Med 1997; 336: 912-18.
69. Gray GA, Schott C, Julou Schaeffer G, Fleming I, Parratt JR, Stoclet JC. The effect of inhibitors of the L-arginine/nitric oxide pathway on endotoxin-induced loss of vascular responsiveness in anaesthetized rats. Br J Pharmacol 1991; 103: 1218-24.
70. Nava E, Palmer RM, Moncada S. The role of nitric oxide in endotoxic shock: Effects of NG-monomethyl-L-arginine. J Cardiovasc Pharmacol 1992; 20 Suppl 12: S132-4.
71. Szabo C, Southan GJ, Thiemermann C. Beneficial effects and improved survival in rodent models of septic shock with S-methylisothiourea sulfate, a potent and selective inhibitor of inducible nitric oxide synthase. Proc Natl Acad Sci U.S.A. 1994; 91: 12472-6.
72. Booke M, Hinder F, McGuire R, Traber LD, Traber DL. Nitric oxide synthase inhibition versus norepinephrine for the treatment of hyperdynamic sepsis in sheep. Crit Care Med 1996; 24: 835-44.
73. Klemm P, Thiemermann C, Winklmaier G, Martorana PA, Henning R. Effects of nitric oxide synthase inhibition combined with nitric oxide inhalation in a porcine model of endotoxin shock. Br J Pharmacol 1995; 114: 363-8.
74. Petros A, Bennett D, Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock [see comments]. Lancet 1991; 338: 1557-8.
75. Geroulanos SS, Cakmacki J. Inhibition of NO synthesis in septic shock. Lancet 1992; 15: 339-435.
76. Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 1994; 28: 34-9.
77. Preiser LP, Roman J-C, Carlier A et al. Methylene blue administration in septic shock: A clinical trial. Crit Care Med 1995; 23: 259-64.
78. Lessauer W. Recombinant soluble TNF receptor proteins protect mice from LPS-induced lethality. Eur J Immunol 1991; 156: 2883-6.
79. Van Zee KJ. Protection against lethal E. Coli bacteremia in baboons by pretreatment with 55-kDa TNF receptor (CD 120a)-Ig fusion protein, Ro 45-2981. J Immunol 1996; 156: 2221-30.
80. Abraham EA, Gutierrez A, Tessler G. Double-blind randomized controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet 1998; 351: 929-33.
81. Cohen JC. INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24: 1431-40.
82. Kumar AK, Ginsburg R. Myocardial cell contractility is depressed by supernatants of endotoxin stimulated THP-1 cells. Crit Care Med 1994; 22: A118.
83. Paulus WJ, Vantrimpont PJ, Shah AM. Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans. Assessment by bicoronary sodium nitroprusside infusion. Circulation 1994; 89: 2070-8.
84. Eskandari MK, Bolgos G, Miller C, Nguyen DT, DeForge LE, Remick DG. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol 1992; 148: 2724-30.
85. Broner CW, Shenep JL, Stidham GL et al. Effect of antioxidants in experimental escherichia coli septicemia. Circ Shock 1989; 29: 77-92.
86. Kunimoto FM, Ogawa T, Fujita R. Inhibition of lipid peroxidation improves survival rate of endotoxaemic rats. Circ Shock 1987; 21: 15-22.
87. Galley HF. The effects of antioxidants in patients with septic shock. Free Rad Biol Med 1997; 23: 768-74.
88. Zimmermann TA, Kuhne S, Vogelsang H, Grutzmann U, Kopprasch R. Selenium administration in patients with sepsis syndrome. A prospective randomized study. Med Klin 1997; 92: 3-4.
89. Szabo C, Thiemermann C, Wu CC, Perretti M, Vane JR. Attenuation of the induction of nitric oxide synthase by endogenous glucocorticoids accounts for endotoxin tolerance in vivo. Proc Natl Acad Sci U.S.A. 1994; 91: 271-5.
90. Hinshaw LBB, Chang BK, Murray AC, Flournoy CK, Passey DJ, Archer RB. Corticosteroid/antibiotic treatment of adrenalectomized dogs challenged with lethal E. Coli. Cir Shock 1985; 16: 265-77.
91. Septic shock co-operative. N Engl J Med 1987; 317: 650.
92. Bone RC, Fisher Jr CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317: 653-8.
93. Fink MP, MacVittie TJ, Casey LC. Inhibition of prostaglandin synthesis restores normal hemodynamics in canine hyperdynamic sepsis. Ann Surg 1984; 200: 619-26.